These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
346 related articles for article (PubMed ID: 33859474)
1. Immunoassay-Amplified Responses Using a Functionalized MoS Chiu NF; Tai MJ; Nurrohman DT; Lin TL; Wang YH; Chen CY Int J Nanomedicine; 2021; 16():2715-2733. PubMed ID: 33859474 [TBL] [Abstract][Full Text] [Related]
2. Clinical Application for Screening Down's Syndrome by Using Carboxylated Graphene Oxide-Based Surface Plasmon Resonance Aptasensors. Chiu NF; Wang YH; Chen CY Int J Nanomedicine; 2020; 15():8131-8149. PubMed ID: 33144830 [TBL] [Abstract][Full Text] [Related]
4. Simultaneous Real-Time Detection of Pregnancy-Associated Plasma Protein-A and -A2 Using a Graphene Oxide-Based Surface Plasmon Resonance Biosensor. Fan SY; Chiu NF; Chen CP; Chang CC; Chen CY Int J Nanomedicine; 2020; 15():2085-2094. PubMed ID: 32273704 [TBL] [Abstract][Full Text] [Related]
5. Development of a bioaffinity SPR immunosensor based on functionalized graphene oxide for the detection of pregnancy-associated plasma protein A2 in human plasma. Chiu NF; Tai MJ; Wu HP; Lin TL; Chen CY Int J Nanomedicine; 2019; 14():6735-6748. PubMed ID: 31686806 [TBL] [Abstract][Full Text] [Related]
6. First trimester maternal serum screening for Down's syndrome: an evaluation of the DPC Immulite 2000 free beta-hCG and pregnancy-associated plasma protein-A assays. Spencer K Ann Clin Biochem; 2005 Jan; 42(Pt 1):30-40. PubMed ID: 15802030 [TBL] [Abstract][Full Text] [Related]
7. Total pregnancy-associated plasma protein A--a first trimester maternal serum marker for Down's syndrome: clinical and technical assessment of a poly-monoclonal enzyme immunoassay. Christiansen M; Jaliashvili I Scand J Clin Lab Invest; 2003; 63(6):407-15. PubMed ID: 14594321 [TBL] [Abstract][Full Text] [Related]
8. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening. Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311 [TBL] [Abstract][Full Text] [Related]
9. Clinical Application of a Graphene Oxide-Based Surface Plasmon Resonance Biosensor to Measure First-Trimester Serum Pregnancy-Associated Plasma Protein-A/A2 Ratio to Predict Preeclampsia. Chen CY; Wang YH; Chen CP; Sun FJ; Chen YY; Huang YJ; Chiu NF Int J Nanomedicine; 2023; 18():7469-7481. PubMed ID: 38090367 [TBL] [Abstract][Full Text] [Related]
10. First trimester screening for Down's syndrome using maternal serum PAPP-A and free beta-hCG in combination with fetal nuchal translucency thickness. Biagiotti R; Brizzi L; Periti E; d'Agata A; Vanzi E; Cariati E Br J Obstet Gynaecol; 1998 Aug; 105(8):917-20. PubMed ID: 9746387 [TBL] [Abstract][Full Text] [Related]
11. Age related detection and false positive rates when screening for Down's syndrome in the first trimester using fetal nuchal translucency and maternal serum free betahCG and PAPP-A. Spencer K BJOG; 2001 Oct; 108(10):1043-6. PubMed ID: 11702835 [TBL] [Abstract][Full Text] [Related]
12. Surface plasmon resonance biosensor for detection of pregnancy associated plasma protein A2 in clinical samples. Bocková M; Chadtová Song X; Gedeonová E; Levová K; Kalousová M; Zima T; Homola J Anal Bioanal Chem; 2016 Oct; 408(26):7265-9. PubMed ID: 27299774 [TBL] [Abstract][Full Text] [Related]
13. [Screening by maternal serum markers for Down's syndrome]. Liu JT; Hao N; Sun NH; Wang FY; Xu YH; Gai MY; Bian XM; Yang JQ Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Apr; 25(2):156-9. PubMed ID: 12905710 [TBL] [Abstract][Full Text] [Related]
14. Combined ultrasound and biochemical screening for Down's syndrome in the first trimester: a Scottish multicentre study. Crossley JA; Aitken DA; Cameron AD; McBride E; Connor JM BJOG; 2002 Jun; 109(6):667-76. PubMed ID: 12118646 [TBL] [Abstract][Full Text] [Related]
15. Cross-trimester repeated measures testing for Down's syndrome screening: an assessment. Wright D; Bradbury I; Malone F; D'Alton M; Summers A; Huang T; Ball S; Baker A; Nix B; Aitken D; Crossley J; Cuckle H; Spencer K Health Technol Assess; 2010 Jul; 14(33):1-80. PubMed ID: 20624355 [TBL] [Abstract][Full Text] [Related]
16. High-Sensitivity Detection of the Lung Cancer Biomarker CYFRA21-1 in Serum Samples Using a Carboxyl-MoS Chiu NF; Yang HT Front Bioeng Biotechnol; 2020; 8():234. PubMed ID: 32274382 [TBL] [Abstract][Full Text] [Related]
17. Undetectable pregnancy-associated plasma protein-A in antenatal serum Down's syndrome screening: a case of assay interference. Williams C; Hambridge K; Petchey M; Martin JA; Spencer K Ann Clin Biochem; 2015 Sep; 52(Pt 5):615-9. PubMed ID: 25995284 [TBL] [Abstract][Full Text] [Related]
18. Antenatal screening for Down's syndrome. Wald NJ; Kennard A; Hackshaw A; McGuire A J Med Screen; 1997; 4(4):181-246. PubMed ID: 9494915 [TBL] [Abstract][Full Text] [Related]
19. Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy. International Prenatal Screening Research Group. Wald NJ; George L; Smith D; Densem JW; Petterson K Br J Obstet Gynaecol; 1996 May; 103(5):407-12. PubMed ID: 8624312 [TBL] [Abstract][Full Text] [Related]